Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine
PFIZER AND BIONTECH CONCLUDE PHASE 3 STUDY OF COVID-19 VACCINE CANDIDATE, MEETING ALL PRIMARY EFFICACY ENDPOINTS Wednesday, November 18, 2020 – 06:59am Primary efficacy analysis demonstrates BNT162b2 to be 95% […]
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Read More »